PT  - JOURNAL ARTICLE
AU  - Abe, Takashi
AU  - Arita, Masanori
TI  - Genomic Surveillance in Japan of AY.29—A New Sub-lineage of SARS-CoV-2 Delta Variant with C5239T and T5514C Mutations
AID  - 10.1101/2021.09.20.21263869
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.20.21263869
4099  - http://medrxiv.org/content/early/2021/09/22/2021.09.20.21263869.short
4100  - http://medrxiv.org/content/early/2021/09/22/2021.09.20.21263869.full
AB  - In the present study, we report a new sub-lineage of the SARS-CoV-2 Delta variant called AY.29, which has C5239T and T5514C mutations. We investigated the monthly trend of AY.29 in Japan within 11,954 Delta variants downloaded on September 3, 2021. Among the total Japanese Delta variants, the AY.29 sub-lineage accounted for 88.4%. In terms of monthly changes, the sequences became predominant in June, and accounted for 93.2% and 94.2% of the reported sequences in July and August, respectively. Furthermore, the number of Delta variants imported from abroad during the Tokyo 2020 Olympics and Paralympics (held in August 2021) was extremely low. Therefore, the epidemic of the new Delta variant is attributable to a newly occurring mutation in Japan.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by JST and CREST (grant number JPMJCR20H1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:It is not necessary to think a further ethics approval/statement, because we use public data provided by GISAID database.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data uses the data registered in GISAID and follows the terms of use of GISAID.